Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital

Background The use of trastuzumab is associated with an increased survival rate in HER2 positive breast cancer patients. However, it is related to different levels of cardiotoxicity leading to treatment discontinuation, which can deprive patients of the benefits of this therapy. Objective This study...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2015-04, Vol.37 (2), p.365-372
Main Authors: Ayres, Lorena Rocha, de Almeida Campos, Marília Silveira, de Oliveira Gozzo, Thais, Martinez, Edson Zangiacomi, Ungari, Andrea Queiróz, de Andrade, Jurandyr Moreira, Pereira, Leonardo Régis Leira
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - adverse effects
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Cardiotoxicity - genetics
Cardiovascular disease
Chemotherapy
Female
Heart Failure - chemically induced
Heart Failure - genetics
Humans
Internal Medicine
Medicine
Medicine & Public Health
Middle Aged
Pharmacology
Pharmacy
Receptor, ErbB-2 - genetics
Research Article
Retrospective Studies
Side effects
Tertiary Care Centers
Toxicity
Trastuzumab - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The use of trastuzumab is associated with an increased survival rate in HER2 positive breast cancer patients. However, it is related to different levels of cardiotoxicity leading to treatment discontinuation, which can deprive patients of the benefits of this therapy. Objective This study aimed to identify the incidence of trastuzumab induced cardiotoxicity (TIC) and the rate of discontinuation of trastuzumab in clinical practice. Possible factors associated with TIC were also investigated. Setting This study was conducted in the General Hospital of the School of Medicine of Ribeirão Preto, University of São Paulo. Methods We retrospectively reviewed the medical records of patients without distant metastasis that started trastuzumab between 2007 and 2011 in the tertiary hospital. TIC was defined as symptomatic heart failure or a decrease in left ventricular ejection fraction (LVEF) by ≥10 % compared to the first echocardiography measurement or to
ISSN:2210-7703
2210-7711
DOI:10.1007/s11096-015-0070-y